- Home
- FBLG vs TURN Comparison
FBLG vs TURN Comparison
Compare FBLG & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBLG
- TURN
- Stock Information
- Founded
- FBLG 2021
- TURN 1981
- Country
- FBLG United States
- TURN United States
- Employees
- FBLG N/A
- TURN N/A
- Industry
- FBLG
- TURN Finance/Investors Services
- Sector
- FBLG
- TURN Finance
- Exchange
- FBLG NYSE
- TURN Nasdaq
- Market Cap
- FBLG 37.1M
- TURN 35.3M
- IPO Year
- FBLG 2024
- TURN N/A
- Fundamental
- Price
- FBLG $1.29
- TURN $3.80
- Analyst Decision
- FBLG Strong Buy
- TURN
- Analyst Count
- FBLG 4
- TURN 0
- Target Price
- FBLG $13.00
- TURN N/A
- AVG Volume (30 Days)
- FBLG 231.6K
- TURN 43.7K
- Earning Date
- FBLG 05-13-2025
- TURN 05-12-2025
- Dividend Yield
- FBLG N/A
- TURN N/A
- EPS Growth
- FBLG N/A
- TURN N/A
- EPS
- FBLG N/A
- TURN N/A
- Revenue
- FBLG N/A
- TURN $194,813.00
- Revenue This Year
- FBLG N/A
- TURN N/A
- Revenue Next Year
- FBLG N/A
- TURN N/A
- P/E Ratio
- FBLG N/A
- TURN N/A
- Revenue Growth
- FBLG N/A
- TURN 254.25
- 52 Week Low
- FBLG $0.76
- TURN $3.12
- 52 Week High
- FBLG $13.59
- TURN $4.20
- Technical
- Relative Strength Index (RSI)
- FBLG 62.17
- TURN 51.81
- Support Level
- FBLG $0.76
- TURN $3.59
- Resistance Level
- FBLG $1.53
- TURN $3.94
- Average True Range (ATR)
- FBLG 0.14
- TURN 0.34
- MACD
- FBLG 0.06
- TURN 0.02
- Stochastic Oscillator
- FBLG 68.71
- TURN 73.03
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.